DiaMedica Therapeutics (DMAC) stock price is $8.63, down 0.52% on the day, as of Oct 21, 2026. It has a market cap of $464.84Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap464.84 Mn
P/E-12.37
Div. Yield0.00
Add ratio to table…
About
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for severe ischemic diseases, with primary programs targeting preeclampsia and fetal growth restriction as well as acute ischemic stroke. The company's lead candidate is DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1 (rhKLK1) protein designed to enhance endothelial health, microcirculatory blood flow, and tissue perfusion by increasing…
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for severe ischemic diseases, with primary programs targeting preeclampsia and fetal growth restriction as well as acute ischemic stroke. The company's lead candidate is DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1 (rhKLK1) protein designed to enhance endothelial health, microcirculatory blood flow, and tissue perfusion by increasing production of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor. DM199 has received Fast Track designation from the U. S. Food and Drug Administration for the treatment of acute ischemic stroke and is being investigated for additional indications including severe acute pancreatitis through a follow-on candidate, DM300.
DiaMedica Therapeutics Inc. does not currently generate revenue from product sales, as its operations are centered on research and development of clinical-stage drug candidates. The company's financial resources are directed toward advancing DM199 through preclinical and clinical trials for preeclampsia, fetal growth restriction, and acute ischemic stroke, as well as developing DM300 for potential use in severe acute pancreatitis. Funding is obtained through equity financing, collaborations, and other capital-raising activities to support ongoing development efforts.
The company operates through the following segments:
Preeclampsia and Fetal Growth Restriction: This segment focuses on the development of DM199 for the treatment of preeclampsia and fetal growth restriction, conditions characterized by impaired placental perfusion and maternal endothelial dysfunction. DM199 is being evaluated in an investigator-sponsored Phase 2 study conducted at Tygerberg Hospital in Cape Town, South Africa, which includes dose-escalation, dose-expansion, and expectant management components for preeclampsia patients, along with a separate study for fetal growth restriction. Interim results from the study have shown statistically significant and sustained reductions in blood pressure up to 24 hours post-infusion, with no evidence of placental transfer and a favorable safety profile. Preparations are underway to initiate a global Phase 2 trial in early-onset preeclampsia in North America and the United Kingdom, following regulatory approval from Health Canada and planned submissions to the UK regulatory authorities.
Acute Ischemic Stroke: This segment centers on the development of DM199 for the treatment of acute ischemic stroke, aiming to extend the therapeutic window beyond current thrombolytic therapies by promoting collateral blood flow and neuroprotection in the ischemic penumbra. The ReMEDy2 Phase 2/3 clinical trial (NCT05065216) is a global, adaptive design, randomized, double-blind, placebo-controlled study enrolling up to 728 patients across approximately 100 sites in the United States, Canada, Georgia, the United Kingdom, and six European countries. The trial evaluates physical recovery using the modified Rankin Scale at day 90, with secondary endpoints including stroke recurrence, NIHSS, and Barthel Index. DM199 has demonstrated a favorable safety profile in prior studies, with transient hypotension observed only at elevated doses and rapidly reversible upon infusion cessation.
DiaMedica Therapeutics Inc. operates in a competitive biopharmaceutical landscape where it faces competition from larger pharmaceutical and biotechnology companies developing therapies for preeclampsia and acute ischemic stroke. In preeclampsia, competitors include Comanche Biopharma with its siRNA candidate CBP-4888 targeting sFlt-1, as well as academic groups investigating repurposed agents like metformin. For acute ischemic stroke, the company competes with established thrombolytics such as alteplase and tenecteplase, mechanical thrombectomy devices, and emerging agents like edaravone/dexborneol, asundexian, and milvexian. DiaMedica's competitive advantages stem from its proprietary recombinant human kallikrein-1 platform, which offers potential benefits over plasma- or porcine-derived KLK1 products used in Asia, including consistent potency, reduced impurity risk, and scalable manufacturing. The company believes DM199 could qualify for 12 years of market exclusivity in the United States under the Biologics Price Competition and Innovation Act if approved.
DiaMedica Therapeutics Inc. serves patients and healthcare providers in the fields of maternal-fetal medicine and neurology, particularly those affected by preeclampsia, fetal growth restriction, and acute ischemic stroke. The company's clinical trials involve pregnant women with preeclampsia at institutions such as Tygerberg Hospital in South Africa, with plans to expand to sites in the United States, Canada, and the United Kingdom. For acute ischemic stroke, trial participants are enrolled at hospitals and stroke centers across North America, Europe, and other global regions, focusing on patients who are ineligible for or have not responded to thrombolytic therapy or mechanical thrombectomy. The company does not currently disclose specific commercial customer names, as it remains in the clinical development stage and has not yet commercialized any products.
Sector:HealthcareSector rationaleDiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing drug candidates such as DM199 and DM300 for the treatment of preeclampsia and acute ischemic stroke. Its core business activity is the research and development of medical therapies, which falls directly under the Biotechnology and Pharmaceuticals industries within the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryDiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), which is a recombinant human tissue kallikrein-1 (rhKLK1) protein. This is a biologic therapy derived from biological science, fitting the description of biotechnology-focused drug development.Classified using BQ-MICSCIK: 0001401040
Bull & bear
Investment Thesis
▲ Bull case
DiaMedica Therapeutics is positioned to capitalize on a significant unmet medical need in fetal growth restriction (FGR), a condition affecting approximately 10% of pregnancies globally with no approved pharmacologic therapies, as evidenced by the recent dosing of the first two patients in the investigator-sponsored Phase 2 trial for FGR, which leverages the same mechanism of action showing promise in preeclampsia—improving uteroplacental perfusion via nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor without crossing the placental barrier, thereby offering a potential disease-modifying approach that could prolong pregnancy and improve neonatal outcomes in a high-risk population where current management is limited to monitoring and timing of delivery.
The company’s strategic focus on expanding its clinical footprint for the ReMEDy2 stroke trial, including site activations in the U.K. and Europe and increased enrollment momentum driven by both higher per-site enrollment rates and a growing number of active sites (now 61 with 25 more expected), positions DiaMedica to achieve its interim analysis guidance in the second half of 2026, with the independent DSMB already recommending continuation without modification after reviewing safety data from the first 100 patients, reducing regulatory and execution risk while increasing the likelihood of a positive efficacy signal that could support a resample size of 300–350 patients based on historical Phase II data.
The recent FDA feedback indicating that the previously completed rat reproductive toxicity study may be acceptable to support a U.S. IND application for DM199 in preeclampsia—provided DiaMedica can demonstrate sufficient exposure, enzymatic activity, and pharmacologic effect in rats—represents a de-risking milestone that could accelerate U.S. trial initiation later in 2026, especially as the company is already advancing its PE study in Canada and the U.K., thereby creating a parallel path to global development and potentially avoiding delays associated with alternative species testing, which management acknowledged as premature to finalize but actively resolving through ongoing FDA alignment.
DiaMedica’s strong cash position of $59.9 million as of December 31, 2025, funded by net proceeds from the July 2025 private placement and at-the-market offering, is sufficient to fund planned clinical studies and corporate operations through the end of 2027, providing a multi-year runway that alleviates near-term financing concerns and allows sustained investment in pipeline advancement across preeclampsia, FGR, and stroke indications without the pressure of dilutive financing events, a critical advantage for a clinical-stage biotech navigating lengthy and costly trials.
The publication of the endothelial triple pathway basal relaxation paper in the Journal of Hypertension, featuring Dr. Luke Laffin as a co-author and highlighting DM199’s ability to reduce blood pressure and lower serum potassium in patients with elevated levels—particularly relevant for chronic kidney disease (CKD) patients at risk of hyperkalemia—suggests an underappreciated secondary opportunity for DM199 beyond its primary indications, with management acknowledging the CKD opportunity as exciting and planning to explore it after near-term focus on preeclampsia and stroke, implying a potential future catalyst that could expand the drug’s addressable market and enhance long-term commercial viability.
DiaMedica Therapeutics is positioned to capitalize on a significant unmet medical need in fetal growth restriction (FGR), a condition affecting approximately 10% of pregnancies globally with no approved pharmacologic therapies, as evidenced by the recent dosing of the first two patients in the investigator-sponsored Phase 2 trial for FGR, which leverages the same mechanism of action showing promise in preeclampsia—improving uteroplacental perfusion via nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor without crossing the placental barrier, thereby offering a potential disease-modifying approach that could prolong pregnancy and improve neonatal outcomes in a high-risk population where current management is limited to monitoring and timing of delivery.
The company’s strategic focus on expanding its clinical footprint for the ReMEDy2 stroke trial, including site activations in the U.K. and Europe and increased enrollment momentum driven by both higher per-site enrollment rates and a growing number of active sites (now 61 with 25 more expected), positions DiaMedica to achieve its interim analysis guidance in the second half of 2026, with the independent DSMB already recommending continuation without modification after reviewing safety data from the first 100 patients, reducing regulatory and execution risk while increasing the likelihood of a positive efficacy signal that could support a resample size of 300–350 patients based on historical Phase II data.
The recent FDA feedback indicating that the previously completed rat reproductive toxicity study may be acceptable to support a U.S. IND application for DM199 in preeclampsia—provided DiaMedica can demonstrate sufficient exposure, enzymatic activity, and pharmacologic effect in rats—represents a de-risking milestone that could accelerate U.S. trial initiation later in 2026, especially as the company is already advancing its PE study in Canada and the U.K., thereby creating a parallel path to global development and potentially avoiding delays associated with alternative species testing, which management acknowledged as premature to finalize but actively resolving through ongoing FDA alignment.
DiaMedica’s strong cash position of $59.9 million as of December 31, 2025, funded by net proceeds from the July 2025 private placement and at-the-market offering, is sufficient to fund planned clinical studies and corporate operations through the end of 2027, providing a multi-year runway that alleviates near-term financing concerns and allows sustained investment in pipeline advancement across preeclampsia, FGR, and stroke indications without the pressure of dilutive financing events, a critical advantage for a clinical-stage biotech navigating lengthy and costly trials.
The publication of the endothelial triple pathway basal relaxation paper in the Journal of Hypertension, featuring Dr. Luke Laffin as a co-author and highlighting DM199’s ability to reduce blood pressure and lower serum potassium in patients with elevated levels—particularly relevant for chronic kidney disease (CKD) patients at risk of hyperkalemia—suggests an underappreciated secondary opportunity for DM199 beyond its primary indications, with management acknowledging the CKD opportunity as exciting and planning to explore it after near-term focus on preeclampsia and stroke, implying a potential future catalyst that could expand the drug’s addressable market and enhance long-term commercial viability.
DiaMedica Therapeutics faces substantial execution risk in its fetal growth restriction (FGR) program despite the promising mechanistic rationale, as the investigator-sponsored Phase 2 trial is open-label, single-arm, and limited to 30 patients with early-onset FGR between 27 and 32 weeks of gestation, making it inherently susceptible to bias and insufficient to support regulatory approval without subsequent larger, controlled trials, and the company has not disclosed any clear path or funding strategy for a pivotal Phase 3 program in FGR, raising concerns that positive early signals may not translate into a viable regulatory pathway given the historical difficulty of demonstrating clinical benefit in placental-mediated disorders.
The ReMEDy2 stroke trial’s interim analysis guidance for the second half of 2026 remains contingent on achieving a drug effect comparable to prior Phase II results, with management explicitly stating that if the interim analysis shows no drug effect, the study will be terminated for lack of efficacy, and if a larger sample size is needed (potentially up to 728 patients), the company will need to reevaluate next steps in light of high prospects for the preeclampsia program, suggesting that resource allocation conflicts could arise and that the trial’s adaptive design introduces uncertainty about whether the study will ever reach a conclusive outcome, especially given past enrollment challenges in the U.S. due to community hospital triage delays.
Although the FDA has indicated that the rat reproductive toxicity study may be acceptable for a U.S. IND in preeclampsia, this is conditional on DiaMedica demonstrating sufficient evidence of DM199 exposure, enzymatic activity, and pharmacologic effect in rats—a requirement the company has not yet fulfilled, as it is only now initiating the pharmacokinetic and pharmacologic activity study, meaning the U.S. IND filing remains delayed and uncertain, with no timeline provided for completion or submission, and the company’s reliance on third-party collaboration for investigator-sponsored trials adds further variability to site activation and enrollment goals, particularly in regions like South Africa where staffing challenges have already slowed the Part 1a expansion cohort despite recent financial support and nurse hiring.
DiaMedica’s cash burn increased to $29.1 million in net cash used in operating activities for full year 2025, up from $22.1 million in 2024, driven by higher R&D expenses ($24.6 million vs. $19.1 million) and G&A costs ($9.8 million vs. $7.6 million), primarily due to global trial expansion, team growth, and share-based compensation, and while the current cash position of $59.9 million is stated to fund operations through 2027, this assumes no acceleration in spending or unexpected delays—such as those seen in the rabbit reproductive tox model failure or site staffing issues—which could rapidly erode the runway if clinical milestones are missed and additional financing becomes necessary on less favorable terms.
The company’s repeated de-emphasis of the chronic kidney disease (CKD) opportunity—despite compelling data from the REDUX trial showing DM199’s ability to lower blood pressure and serum potassium in hyperkalemia-prone patients—suggests a lack of prioritization that may reflect internal skepticism about the commercial viability or regulatory path for this indication, especially given that management explicitly stated they are “really focused here near term” on preeclampsia and stroke and will only look at CKD “at the appropriate time,” which could signal that this potential secondary market is being deprioritized indefinitely, limiting upside diversification and increasing reliance on the success of higher-risk obstetric and neurologic indications.
DiaMedica Therapeutics faces substantial execution risk in its fetal growth restriction (FGR) program despite the promising mechanistic rationale, as the investigator-sponsored Phase 2 trial is open-label, single-arm, and limited to 30 patients with early-onset FGR between 27 and 32 weeks of gestation, making it inherently susceptible to bias and insufficient to support regulatory approval without subsequent larger, controlled trials, and the company has not disclosed any clear path or funding strategy for a pivotal Phase 3 program in FGR, raising concerns that positive early signals may not translate into a viable regulatory pathway given the historical difficulty of demonstrating clinical benefit in placental-mediated disorders.
The ReMEDy2 stroke trial’s interim analysis guidance for the second half of 2026 remains contingent on achieving a drug effect comparable to prior Phase II results, with management explicitly stating that if the interim analysis shows no drug effect, the study will be terminated for lack of efficacy, and if a larger sample size is needed (potentially up to 728 patients), the company will need to reevaluate next steps in light of high prospects for the preeclampsia program, suggesting that resource allocation conflicts could arise and that the trial’s adaptive design introduces uncertainty about whether the study will ever reach a conclusive outcome, especially given past enrollment challenges in the U.S. due to community hospital triage delays.
Although the FDA has indicated that the rat reproductive toxicity study may be acceptable for a U.S. IND in preeclampsia, this is conditional on DiaMedica demonstrating sufficient evidence of DM199 exposure, enzymatic activity, and pharmacologic effect in rats—a requirement the company has not yet fulfilled, as it is only now initiating the pharmacokinetic and pharmacologic activity study, meaning the U.S. IND filing remains delayed and uncertain, with no timeline provided for completion or submission, and the company’s reliance on third-party collaboration for investigator-sponsored trials adds further variability to site activation and enrollment goals, particularly in regions like South Africa where staffing challenges have already slowed the Part 1a expansion cohort despite recent financial support and nurse hiring.
DiaMedica’s cash burn increased to $29.1 million in net cash used in operating activities for full year 2025, up from $22.1 million in 2024, driven by higher R&D expenses ($24.6 million vs. $19.1 million) and G&A costs ($9.8 million vs. $7.6 million), primarily due to global trial expansion, team growth, and share-based compensation, and while the current cash position of $59.9 million is stated to fund operations through 2027, this assumes no acceleration in spending or unexpected delays—such as those seen in the rabbit reproductive tox model failure or site staffing issues—which could rapidly erode the runway if clinical milestones are missed and additional financing becomes necessary on less favorable terms.
The company’s repeated de-emphasis of the chronic kidney disease (CKD) opportunity—despite compelling data from the REDUX trial showing DM199’s ability to lower blood pressure and serum potassium in hyperkalemia-prone patients—suggests a lack of prioritization that may reflect internal skepticism about the commercial viability or regulatory path for this indication, especially given that management explicitly stated they are “really focused here near term” on preeclampsia and stroke and will only look at CKD “at the appropriate time,” which could signal that this potential secondary market is being deprioritized indefinitely, limiting upside diversification and increasing reliance on the success of higher-risk obstetric and neurologic indications.